The firm is commercializing and developing treatments for various diseases of the cornea. Its potential market size is rather small, but the company has little apparent direct competition and has ...

setting the stage for a major shake-up in kidney disease treatment. With chronic kidney disease affecting 37 million U.S. adults40% of them with diabetesthis approval unlocks a massive new market ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease ... a replacement for other treatments for disease management such ...

The medication is now approved to lessen the risk of kidney disease progression ... potentially providing crucial treatment options for millions of adults with type 2 diabetes and CKD.

Treatments like dialysis or a kidney transplant ... “I‘ve been studying polycystic kidney disease for 30 years and this is the most significant discovery that I’ve ever been a part of ...

The report found death rates dropped during the survey period for all 10 leading causes of death except kidney disease, which increased by 1.5%. The good news is that 80% of cardiovascular disease ...

According to a 2019 review, up to 84% of people with end stage chronic kidney disease develop pruritus. The authors state that recent advancements in dialysis treatments have helped bring the ...

A team of researchers at Western Michigan University Homer Stryker M.D. School of Medicine has made a monumental breakthrough in understanding autosomal dominant polycystic kidney disease (ADPKD ...